Dati clinici – bibliografia

Ballantyne, A. (2020), How should we think about clinical data ownership? Journal of Medical Ethics; 46, 289–294

Caso R.(2021), Pandemia e vaccini: scienza aperta o proprietà intellettuale?, Riv. crit. dir. priv., 267-286

Correa C. (2002), Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the TRIPS
Agreement, South Centre

Doshi, P. (2022), Covid-19 vaccines and treatments: we must have raw data, now, British Medical Journal, 22 January 2022

Gaessler, F., & Wagner, S. (2020), Patents, Data Exclusivity, and the Development of New Drugs. The Review of Economics and Statistics, 1-49

Garattini S. (2022), Brevettare la salute? Una medicina senza mercato, Il Mulino

Guarda P. (2021), Il regime giuridico dei dati della ricerca scientifica, Editoriale Scientifica

Haug C. (2016), From Patient to Patient – Sharing the Data from Clinical Trials, The New England Journal of Medicine, June 23

Junod, V. (2004), Drug Marketing Exclusivity under United States and European Union Law. Food and Drug Law Journal, 59(4), 479-518

Lemmens T., Telfer C. (2012), Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency, 38 American Journal of Law and Medicine, 63

Levy, K., Merritt J. D. (2016), When open data is a Trojan Horse. The weaponization of transparency in science and governance. Big
Data & Society, 3(1), 1-6

Leptin M. (2012), Open Access – Pass the Buck. Science, 335(6074)
Nosek B.A. et al. (2015), Promoting an open research culture. Science, 348(6242), 1422-1425

Marengo, Luigi and Dosi, Giovanni and Staccioli, Jacopo and Virgillito, Maria Enrica, Big Pharma and Monopoly Capitalism: A Long-Term View. Available at SSRN: https://ssrn.com/abstract=4092494 or http://dx.doi.org/10.2139/ssrn.4092494

Prasad, V. et al. (2013), A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. Aug;88(8): p. 790-8

Minssen T. et al. (2020), Clinical trial data transparency and GDPR compliance: Implications for data sharing and open innovation, in
Science & Public Policy, 1-11

Ragavan S. (2018), The Drug Debate: Data Exclusivity is the New Way to Delay Generics, Connecticut Law Review Online, Vol. 50, No. 2,Texas A&M University School of Law Legal Studies Research Paper No. 18-39

Reichman J.H. (2009), Rethinking The Role Of Clinical Trial Data In International Intellectual Property Law: The Case For A Public
Goods Approach, 13 Marq. Intell. Prop. L. Rev. 1

Ross J.S. (2016), Clinical Research Data Sharing: What an Open Science World Means for Researchers Involved in Evidence
Synthesis, in Systematic Revs., vol. 5, 15

Santos Rutschman A. (2021), Vaccine Clinical Trials and Data Infrastructure, Saint Louis University School of Law, Legal Studies
Research Paper Series, No. 2021-01

Schneider, Giulia, Conforming Intellectual Property and Privacy Restraints to the Right to Health and the Right to Information in Clinical Trials Data (April 30, 2015). Available at SSRN: https://ssrn.com/abstract=2600921 or http://dx.doi.org/10.2139/ssrn.2600921

Sigismondo, S. (2021), Epistemic Corruption, the Pharmaceutical Industry, and the Body of Medical Science, Front. Res. Metr. Anal.

Shaver L. (2010), The Right to Science and Culture, Wisconsin Law Review 121

Stiglitz J.E. (2008), Economic Foundations of Intellectual Property Rights

‘t Hoen, E.F.M. et al. (2017), Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European
Union: A proposal for greater coherence in European pharmaceutical legislation. Journal of Pharmaceutical Policy and Practice, 10(1),

Yu P.K. (2019), Data Exclusivities in the Age of Big Data, Biologics, and Plurilaterals, Texas A&M Law Review Volume 6 Issue 1

Zaitchik A. (2022), Owning the Sun: A People’s History of Monopoly Medicine from Aspirin to COVID-19 Vaccines, Counterpo